 This review evaluates the efficacy and safety of Chinese herbal medicine, CHM, treatments for psoriasis vulgaris using randomized controlled trials, RCTs. Seven studies were included, with four subgrouped and pooled in meta-analysis, to evaluate treatment effective rate for posi-60 or above. Another five studies were subgrouped and evaluated for posi-score change. Only one study presented dermatology life quality index data, which favored CHM. Two studies presented data on psoriasis-related inflammatory cell signalling protein tumor necrosis factor A, TNFA. No serious adverse events were reported, but variation between CHM interventions, outcome measures, and the quality of included studies limit the conclusions of this review. Further rigorous RCTs utilizing reliable, validated symptom, and koal outcome measures are recommended. This article was authored by Sheftan Parker, Claire Shuaiqing Zhong, Jason Jingjie Yu, and others. We are article.tv, links in the description below.